The investors in ImmunityBio, Inc.'s (NASDAQ:IBRX) will be rubbing their hands together with glee today, after the share price leapt 25% to US$2.51 in the week following its quarterly results. Revenues came in at US$17m, in line with expectations, while statutory losses per share were substantially higher than expected, at US$0.15 per share. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on ImmunityBio after the latest results.

Our free stock report includes 3 warning signs investors should be aware of before investing in ImmunityBio. Read for free now.NasdaqGS:IBRX Earnings and Revenue Growth May 14th 2025

Taking into account the latest results, the most recent consensus for ImmunityBio from three analysts is for revenues of US$107.7m in 2025. If met, it would imply a huge 245% increase on its revenue over the past 12 months. Per-share losses are supposed to see a sharp uptick, reaching US$0.51. Before this earnings announcement, the analysts had been modelling revenues of US$104.7m and losses of US$0.51 per share in 2025.

View our latest analysis for ImmunityBio

The consensus price target rose 6.7% to US$13.00, with the analysts encouraged by the improved revenue outlook even though the company remains lossmaking. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values ImmunityBio at US$30.00 per share, while the most bearish prices it at US$6.00. As you can see the range of estimates is wide, with the lowest valuation coming in at less than half the most bullish estimate, suggesting there are some strongly diverging views on how analysts think this business will perform. With this in mind, we wouldn't rely too heavily the consensus price target, as it is just an average and analysts clearly have some deeply divergent views on the business.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the ImmunityBio's past performance and to peers in the same industry. The analysts are definitely expecting ImmunityBio's growth to accelerate, with the forecast 4x annualised growth to the end of 2025 ranking favourably alongside historical growth of 136% per annum over the past three years. Compare this with other companies in the same industry, which are forecast to grow their revenue 17% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that ImmunityBio is expected to grow much faster than its industry.

Story Continues

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for ImmunityBio going out to 2027, and you can see them free on our platform here..

Before you take the next step you should know about the 3 warning signs for ImmunityBio (1 makes us a bit uncomfortable!) that we have uncovered.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments